Skip to main content
OpenTrials
Completed

NCT Number: NCT02337608

Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative Colitis

* Approximately 60 patients suffering from moderate to severe ulcerative colitis will be evaluated for improvement of disease activity (efficacy) when taking GLPG1205 or matching placebo once daily for 12 weeks in addition to their stable background treatment. * During the course of the study, patients will also be examined for any side effects that may occur (safety and tolerability), and the amount of GLPG1205 present in the blood (Pharmacokinetics) as well as the effects of GLPG1205 on disease- and mechanism of action-related parameters (Pharmacodynamics) in blood, stool and colonic biopsies will be determined.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

St. Pierre University Hospital Center, Brussels, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female subjects between 18 and 75 years
  • Documented history of UC
  • Presence of active UC for a minimum period of 14 days prior to screening and spread beyond the rectum, Mayo score ≥ 6 with rectal bleeding score ≥ 1 and endoscopy score ≥ 2
  • Absence of infectious colitis
  • Tumor necrosis factor alpha (TNFα) inhibitor-naive subjects should have failed at least 1 prior conventional therapy
  • Continuation of concurrent treatment with oral steroids (≤30 mg prednisolone eq/day), immunosuppressants and 5-aminosalicylates at stable dose is allowed
  • Female subjects must have a negative blood pregnancy test, unless they are surgically sterile, had a hysterectomy, or have been postmenopausal for at least 1 year
  • Subjects will have to use highly effective contraceptive methods

Exclusion criteria

  • History of sensitivity to any component of the study drug, or a history of drug or other allergy
  • Any concurrent illness, condition, disability, or clinically significant abnormality that, in the investigator's opinion, represents a safety risk for the subject's participation, may affect the interpretation of data, or may prevent the subject from safely completing the assessments
  • History of significant psychological, neurologic, hepatic, renal, endocrine, cardiovascular, GI (other than UC), pulmonary, or metabolic disease
  • History of active infections requiring intravenous antibiotics within the past 4 weeks prior to screening.
  • History of malignancy within the past 5 years; presence or history of intestinal malignancy
  • History of bowel surgery within 6 months prior to screening; history of colon resection with < 30 cm of the colon remaining
  • Suspicion of Crohn's disease, indeterminate colitis, microscopic colitis, ischemic colitis, diverticular disease-associated colitis, or radiation-induced colitis
  • Subject who has received non-permitted UC therapies within specified timeframes, depending on the medication, as stated in the protocol
  • Subject who is pregnant or lactating

Treatment and study plan

GLPG1205

Drug

GLPG1205 daily dosing in the morning for 12 weeks

Placebo

Drug

placebo daily dosing in the morning daily for 12 weeks

Primary outcomes

  1. Changes in Mayo score at Week 8

    Time frame: Screening and Week 8

    To evaluate the efficacy of GLPG1205 in terms of changes in Mayo score comparing results at Week 8 with baseline between GLPG1205 treated subjects and placebo subjects

Secondary outcomes

  1. Changes in partial Mayo score

    Time frame: From Screening to Week 12

    To evaluate the efficacy of GLPG1205 in terms of changes in partial Mayo score comparing results with baseline between GLPG1205 treated subjects and placebo subjects at every visit up to Week 12

  2. Histological response rate

    Time frame: Screening and Week 8

    To evaluate the efficacy of GLPG1205 in terms of histological response rate by use of the histopathological Geboes index comparing results at Week 8 with baseline between GLPG1205 treated subjects and placebo subjects

  3. Number of subjects with adverse events

    Time frame: From Screening to Week 16

    To evaluate the safety and tolerability of GLPG1205 between GLPG1205 treated subjects and placebo subjects in terms of adverse events at every visit

  4. Number of subjects with abnormal laboratory parameters

    Time frame: From Screening to Week 16

    To evaluate the safety and tolerability of GLPG1205 between GLPG1205 treated subjects and placebo subjects in terms of abnormal laboratory parameters at every visit

  5. Number of subjects with abnormal vital signs

    Time frame: From Screening to Week 16

    To evaluate the safety and tolerability of GLPG1205 between GLPG1205 treated subjects and placebo subjects in terms of abnormal vital signs at every visit

  6. Number of subjects with abnormal electrocardiogram

    Time frame: From Screening to Week 16

    To evaluate the safety and tolerability of GLPG1205 between GLPG1205 treated subjects and placebo subjects in terms of abnormal electrocardiograms at every visit

  7. Number of subjects with abnormal physical examination

    Time frame: From Screening to Week 16

    To evaluate the safety and tolerability of GLPG1205 between GLPG1205 treated subjects and placebo subjects in terms of abnormal physical examination at every visit

  8. The plasma levels of GLPG1205

    Time frame: Week 4, 8 and 12

    To characterize the pharmacokinetics (PK) of GLPG1205 by measuring the amount in plasma at Week 4, 8 and 12

  9. Changes in serum C-reactive protein (CRP) levels

    Time frame: From Screening to Week 16

    To characterize the pharmacodynamics (PD) of GLPG1205 by measuring the levels of C-reactive protein in serum at every visit

  10. Changes in faecal calprotectin levels

    Time frame: From Screening to Week 12

    To characterize the pharmacodynamics (PD) of GLPG1205 by measuring the levels of faecal calprotectin in stool at every visit up to Week 12

  11. Changes in myeloperoxidase (MPO) levels in colonic biopsies

    Time frame: Screening and Week 8

    To characterize the pharmacodynamics (PD) of GLPG1205 by measuring the levels of myeloperoxidase (MPO) in colonic biopsies at Screening and Week 8

Sponsors and collaborators

Lead sponsor

Lakefront Biotherapeutics NV

Industry

Registry information

Official study title

Phase II, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Patients With Moderate to Severe Ulcerative Colitis

Acronym: ORIGIN

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Jan 13, 2015
Registry last updated
Nov 20, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.